Products
Data
Feature
Plans
Request Demo
Sign Up for Free
Blog
Valuable Targets
Advanced Tech.
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
IGKV3D-15 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of IGKV3D-15 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
IGKV3D-7 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of IGKV3D-7 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
IGKV3D-20 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of IGKV3D-20 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
IGKV5-2 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of IGKV5-2 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
IGKV4-1 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of IGKV4-1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
IGKV3-15 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of IGKV3-15 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
IGKV3-20 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of IGKV3-20 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
IGKV3-7 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of IGKV3-7 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
IGKV3D-11 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of IGKV3D-11 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
IGKV3-11 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of IGKV3-11 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
IGKV2D-28 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of IGKV2D-28 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
IGKV2D-40 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of IGKV2D-40 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
<
1
<<
194
195
196
197
198
>>
2926
>